

()

I

()

()

I

()

I

mRNA ET-I

()

()

ET-I

stellat cells

()

()

RNA

I

()

I

()

mRNA ET-I

()

)

(

I

(Endothelin-I Assay Kit(L) -IBL)

27165 code number

I

(ANOVA)

Pearson's coefficient of correlation

C B

I

child's score

(%)

(%)

(%)

(%)

(%)

(%)

(%)

(%)

($PO_2 < 80\text{mmHg}$)

(+)

(+++)

(++)

(Sig = 0.503) pearson correlation = 0.097

(%)

		pH
/	/	Supine
/	/	Upright
PaO2(MM Hg)		
/	/	Supine
/	/	Upright
PaCO2(MM Hg)		
/	/	Supine
/	/	Upright
SaO2 (%)		
/	/	Supine
/	/	Upright
AaPO2(mmHg)		
/	/	

() HPS I
 / pg/ml
 % / / pg/ml
 %
 I
 / pg/ml
)
 I
 (/ pg/ml)
 (/ pg/ml)
 HPS Child-score (P= /)
 ()
 C HPS
 I
 Child-score C /
 /

(Sig = 0.466) pearson correlation = 0.106

Andrivet () Child-score C
 (mean Pa_{o2}, 64 mm Hg)
 () (%) C
 (%) C (%)
 HPS D B (%)
 (%) (%)
 C B
 ()) B
) C (non- HPS HPS
 (non-HPS HPS
 () HPS
 HPS
 I (P= /)
 (/ pg/ml) Pao₂
 () HPS (%)
 () Pao₂
 P= /
 I ()
 %
 ()
 ()

REFERENCES

-
- 1- Vaughan RB, Angus PW, Chin-Dusting JPF. Evidence for altered vascular responses to exogenous endothelin I in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation. *Gut* 2003; 52: 1505-10.
 - 2- Teder P, Noble WP. Endothelin I in Pulmonary Inflammation and Fibrosis. *Am J Resp Cell Molec Bio* 2000; 23(1): 7-10.
 - 3- Tran Duc AT, Schwab AJ, Simard A. Reduction in hepatic endothelin I clearance in cirrhosis. *J Clin Sci* 2003; 105(2):227-34.
 - 4- Moore K. Endothelin and vascular function in liver disease. *Gut* 2004; 53:159-61.
 - 5- Kojima H, Sakurai S, Kuriyama S. Endothelin I plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with sub-type A in vivo. *J Hepatol* 2001; 34: 805-11.
 - 6- Abrams GA, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. *Gastroenterology* 1995; 109(4): 1283-8.
 - 7- Kuddus RH, Nalesnik MA, Subbotin VM. Enhanced synthesis and reduced metabolism of endothelin I (ET I) by hepatocytes-an important mechanism of increased endogenous levels of ET I in liver cirrhosis. *J Hepatology* 2000; 33(5): 725-32.
 - 8- Colle IO, Moreau R, Godinho E. Portopulmonary hypertension: an increasingly important complication of cirrhosis. *Hepatology* 2003; 37: 401-9.
 - 9- Zhang M, Luo B, Chen SH. Endothelin I stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. *Am Physiol Soc* 1999; G 944-52.
 - 10- Anand AC, Mukherjee D, Rao KS. Hepatopulmonary syndrome prevalence and clinical profile. *Indian J Gastroenterol* 2001; 2(1): 24-7.
 - 11- Schonigor-Hckel M, Fuhraman V. Prognostic significance of the hepatopulmonary syndrome in patient with cirrhosis. *Gastroenterology* 2003; 125(4): 1042-52.
 - 12- Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Won F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. *Gut* 2003; 52: 1355-62.
 - 13- Leivas A, Jiménez W, Bruix J, Boix L, Bosch J, Arroyo V, et al. Gene expression of endothelin I and ETA and ETB receptors in human cirrhosis: relationship with hepatic hemodynamics hormonal laboratory and liver unit. *J Vasc Res* 1998; 35: 186-93.
 - 14- Krowka MJ, Wiseman GA, Burnett OL, Spivey JR, Therneau T, Porayko MK, et al. Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease. *Chest* 2000; 118: 615-24.
 - 15- De BK, Sen S, Biswas PK, Biswas J, Maity AK. Clinical and haemodynamic aspects of hepatopulmonary syndrome in Indian patients with cirrhosis. *J Gastroenterol Hepatol* 2000; 15(4): 412-6.
 - 16- Xi-Xian Yao, Shu-Lin Jiang, Dong-Mei Yao. Current research of hepatic cirrhosis in China. *World J Gastroenterol* 2005; 11(5): 617-22.

-
- 17- Helmy A. Responses to endothelin I in patients with advanced cirrhosis before and after liver transplantation. *Gut* 2004; 53: 470-1.
 - 18- Sibinović SR, Nagorni A, Raičević R, Brzački V, Stojanović M, Stojanov DB, et al. Hepatorenal syndrome pathophysiological, clinical and treatment considerations. *Acta Fac Med Naiss* 2004; 21(1): 9-14.
 - 19- Dinh-Xuan AT, Naeije R. The hepatopulmonary syndrome: no way out. *Eur Resp J* 2004; 23:661-2.
 - 20- King AJ, Pfeffer JM, Pfeffer MA, Brenner BM. Systemic hemodynamic effects of endothelin in rats. *Heart Circ Physiol* 1990; 258: H787-H792.
 - 21- Lange PA, Stoller JK. The hepatopulmonary syndrome. *Ann Int Med* 1995; 22(7): 521-9.
 - 22- Aladag M, Gurakar A, Nizami I, Dahr AS, Wright H, Sebastian A, et al. Postoperative pulmonary complications among cirrhotic individuals. *Turk J Gastroenterol* 2004; 15(4): 207-12.
 - 23- Gins P, Sal J, Jimnez W, Inglada L, Navasa M, Clria J, et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. *Gastroenterology* 1993; 105(1): 229-36.
 - 24- Beatriz L, Lima G, Alex VC, Pazin-filho A, Whemberton M, Jose AB, et al. Frequency, clinical characteristics and respiratory parameters of hepatopulmonary syndrome. *Mayo Clin Proc* 2004; 79: 42-8.
 - 25- Rodríguez-Roisin R, Krowka MJ, Hervé Ph, Fallon MB. Pulmonary–hepatic vascular disorders (PHD). *Eur Resp J* 2004; 24: 861-80.